Torii

AZ prepares to file COPD triple, taking on rival GSK

AZ has previously said it will file for approval in Japan and China before the end of this year, and in the US and Europe in early 2019.

New data keeps AbbVie’s star pipeline therapies on track

And for good measure Pfizer is developing a topical formulation of Xeljanz for atopic dermatitis, an approach also taken by Torii Pharma with its phase II candidate JTE-052.

Takeda rebels take aim at Shire acquisition

Shareholder group concerned about $30bn debt burden. Opposition to Takeda’s yet-to-be-finalised $63bn takeover of Shire appears to be building among some shareholders in Japan. ... CEO Christophe Weber – the first non-Japanese executive to hold the

NICE U-turn on Crystiva for rare bone disease

The U-turn is good news for the Japan company, which negotiated on the price of the treatment behind closed doors after the NICE's   conclusion that the drug wasn’t

The Creative Floor reveal finalists, Lucid’s Louise Verrall hosts pitch session and Star celebrates 16 years

USA, the EU, Australia, Japan, India, the Philippines and the Middle East.

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]